Atea Pharmaceuticals (NASDAQ:AVIR) Director Bruno Lucidi Sells 6,741 Shares of Stock

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruno Lucidi sold 6,741 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $4.03, for a total value of $27,166.23. Following the completion of the sale, the director owned 157,237 shares of the company’s stock, valued at $633,665.11. This represents a 4.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Bruno Lucidi also recently made the following trade(s):

  • On Thursday, November 19th, Bruno Lucidi sold 22,619 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $3.94, for a total value of $89,118.86.

Atea Pharmaceuticals Trading Down 1.5%

AVIR opened at $3.93 on Friday. The stock’s 50 day simple moving average is $4.68 and its 200-day simple moving average is $4.94. The stock has a market cap of $315.58 million, a PE ratio of -2.02 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 1 year low of $2.92 and a 1 year high of $6.45.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.11. Equities analysts forecast that Atea Pharmaceuticals, Inc. will post -1.60 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on AVIR shares. Morgan Stanley raised their price objective on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

Get Our Latest Stock Analysis on Atea Pharmaceuticals

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AVIR. Empowered Funds LLC bought a new position in Atea Pharmaceuticals during the 3rd quarter valued at about $475,000. Engineers Gate Manager LP bought a new position in Atea Pharmaceuticals in the 2nd quarter valued at $78,000. Spark Investment Management LLC acquired a new stake in Atea Pharmaceuticals in the second quarter worth about $75,000. Headlands Technologies LLC acquired a new stake in Atea Pharmaceuticals in the second quarter worth about $77,000. Finally, Wellington Management Group LLP raised its holdings in Atea Pharmaceuticals by 262.7% during the 2nd quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock worth $962,000 after purchasing an additional 149,776 shares during the last quarter. 86.67% of the stock is owned by institutional investors.

Atea Pharmaceuticals News Summary

These are some of the AVIR news items that stood out recently:

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Recommended Stories

Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.